Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Japan's PMDA now accepts Approval documents in English languages on certain conditions.
The common technical document is one of the items Japan's PMDA now accepts in English. • Source: Shutterstock

Japan has decided to expand its language capability to encourage foreign firms to enter its pharmaceutical market.

The country’s Ministry of Health, Labour and Welfare (MHLW) announced on 6 September that it now allows documents in the English for approval filings in order to ease the application process for non-Japanese firms under certain conditions.

Breaking Barriers: Japan's PMDA To Open First Global Office, In D.C.
Through a new full-time office in the US capital, Japan's drug regulator aims to provide essential regulatory information to help US bioventures enter the Japanese market at an early stage.
Discover the full story

For non-Japanese pharmaceutical firms without any offices or branches in the country, the MHLW allows all documents for approval filing to be submitted in English, including the Common Technical Document (CTD) and products’ inserts “for a certain period of time,” the ministry said.

English applications will be acceptable for three categories of drugs: drugs containing a new active ingredient, new combination prescription drugs, and drugs with a new route of administration.

Any firm planning to submit approval documents in English must consult the Office of Review Management at Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the MHLW added.

The ministry said expanding the allowance for English language documents was a “trial attempt” for an undecided time to address the so-called drug gap between Japan and the global market.

Japan officially processes legal/bureaucratic documents only in Japanese because it is the only official language.

Since 2001, the ministry has allowed CTD modules 3, 4, and 5 to be submitted in English. However, to address the language barrier and encourage more innovative foreign products to enter the Japanese market, the country’s MHLW issued several notices in English while establishing the first PMDA foreign offices in Washington D.C. and Bangkok, Thailand.

While the PMDA Bangkok office is aimed at expanding its collaboration with ASEAN authorities, the D.C. office is designed to accept consultations from US firms for free and in English to encourage their entry into the Japanese market.

To fill the drug gap, the MHLW has implemented multiple measures, including a waiver of Japanese Phase I studies at the end of 2023, which seemingly attracted more Chinese firms’ global Phase III trials into the country. (Also see "Japan Planning To Expand Phase I Waivers" - Pink Sheet, 5 October, 2023.) and (Also see "Multiple Chinese Firms Expand Global Phase III Trials To Japan" - Scrip, 4 September, 2024.)

The ministry is also planning to claim a JPY270m ($1.9m) budget next year to build a one-stop consultation counter to help non-Japanese pharmaceutical firms and startups identify Japanese sites for their clinical trials. The counter is expected to operate under the National Centers for Advanced and Specialized Medicine in Japan (NC).

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the topic areas, the coverage format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard. The survey should only take seven minutes to complete, and you get the chance to win an Amazon gift voucher just by taking part. The deadline for responses is 17 September. Take the survey. Thank you!

More from Japan

Welireg Among Japan Recommendations; Economic Policy Raises Hopes Of Higher Prices

 
• By 

Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.

Citeline Japan Awards 2025 - Enter Now!

 

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By 

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

More from Asia

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

New Era Begins In Korea: Policy Predictions For Biopharma

 
• By 

As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.

Australia Looks To Modernize Human Tissue Laws, Improving Access For Researchers

 

Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.